Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial  by Craddock, Charles et al.
C. Craddock et al. / Biol Blood Marrow Transplant 22 (2016) 378e393 38529. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-
tositumomab (anti-CD20), etoposide, cyclophosphamide, and autolo-
gous stem cell transplantation for relapsed B-cell lymphomas. Blood.
2000;96:2934-2942.
30. Fromm JR, Kussick SJ, Wood BL. Identiﬁcation and puriﬁcation of
classical Hodgkin cells from lymph nodes by ﬂow cytometry and ﬂow
cytometric cell sorting. Am J Clin Pathol. 2006;126:764-780.
31. Fromm JR, Thomas A, Wood BL. Flow cytometry can diagnose classical
hodgkin lymphoma in lymph nodes with high sensitivity and speci-
ﬁcity. Am J Clin Pathol. 2009;131:322-332.Financial disclosure: See Acknowledgments on page 389.
* Correspondence and reprint requests: Charles Craddock, Centre for
Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United
Kingdom B15 2TH.
E-mail address: charles.craddock@uhb.nhs.uk (C. Craddock).
http://dx.doi.org/10.1016/j.bbmt.2015.09.004
1083-8791/ 2016 American Society for Blood andMarrow Transplantation.
Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).32. Wu D, Allen CT, Fromm JR. Flow cytometry of ALK-negative anaplastic
large cell lymphoma of breast implant-associated effusion and capsular
tissue. Cytometry B Clin Cytom. 2015;88:58-63.
33. Wu D, Wood BL, Fromm JR. Flow cytometry for non-Hodgkin and
classical Hodgkin lymphoma. Methods Mol Biol. 2013;971:27-47.
34. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and stan-
dardization of PCR primers and protocols for detection of clonal
immunoglobulin and T-cell receptor gene recombinations in suspect
lymphoproliferations: report of the BIOMED-2 Concerted Action
BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.Tolerability and Clinical Activity of Post-Transplantation
Azacitidine in Patients Allografted for Acute Myeloid Leukemia
Treated on the RICAZA TrialCharles Craddock 1,2,*, Nadira Jilani 1,2, Shamyla Siddique 1,2, Christina Yap 1,2, Josephine Khan 2,
Sandeep Nagra 1, Janice Ward 1, Paul Ferguson 1,2,3, Peter Hazlewood 1,2, Richard Buka 1,
Paresh Vyas 4, Oliver Goodyear 3, Eleni Tholouli 5, Charles Crawley 6, Nigel Russell 7, Jenny Byrne 7,
Ram Malladi 1,2,3, John Snowden 8, Mike Dennis 9
1Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom
2Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
3 School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
4MRC Molecular Haematology Unit and Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
5Department of Clinical Haematology, Manchester Royal Inﬁrmary, Manchester, United Kingdom
6Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
7Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
8Department of Haematology, Shefﬁeld Teaching Hospitals NHS Trust and Department of Oncology, University of Shefﬁeld, United Kingdom
9Haematology and Transplant Unit, The Christie NHS Foundation Trust, Manchester, United KingdomArticle history:
Received 22 December 2014
Accepted 2 September 2015
Key Words:
Acute myeloid leukemia
Relapse
Azacitidine
Tumor antigensa b s t r a c t
Disease relapse is the major causes of treatment failure after allogeneic stem cell transplantation (SCT) in
patients with acute myeloid leukemia (AML). As well as demonstrating signiﬁcant clinical activity in AML,
azacitidine (AZA) upregulates putative tumor antigens, inducing a CD8þ T cell response with the potential to
augment a graft-versus-leukemia effect. We, therefore, studied the feasibility and clinical sequelae of the
administration of AZA during the ﬁrst year after transplantation in 51 patients with AML undergoing allo-
geneic SCT. Fourteen patients did not commence AZA either because of transplantation complications or
withdrawal of consent. Thirty-seven patients commenced AZA at a median of 54 days (range, 40 to 194 days)
after transplantation, which was well tolerated in the majority of patients. Thirty-one patients completed 3 or
more cycles of AZA. Sixteen patients relapsed at a median time of 8 months after transplantation. No patient
developed extensive chronic graft-versus-host disease. The induction of a post-transplantation CD8þ T cell
response to 1 or more tumor-speciﬁc peptides was studied in 28 patients. Induction of a CD8þ T cell response
was associated with a reduced risk of disease relapse (hazard ratio [HR], .30; 95% conﬁdence interval [CI],
.10 to .85; P ¼ .02) and improved relapse-free survival (HR, .29; 95% CI, .10 to .83; P ¼ .02) taking into account
death as a competing risk. In conclusion, AZA is well tolerated after transplantation and appears to have the
capacity to reduce the relapse risk in patients who demonstrate a CD8þ T cell response to tumor antigens.
These observations require conﬁrmation in a prospective clinical trial.
 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).INTRODUCTION
Allogeneic stem cell transplantation (SCT) represents an
increasingly important curative option in adults with high-
risk acute myeloid leukemia (AML) [1]. To a large degree,this reﬂects the improved tolerability of reduced-intensity
conditioning (RIC) regimens, which have permitted the
extension of a potentially curative graft-versus-leukemia
(GVL) effect to patients up to their eighth decade [2-4].
Although the increased availability of allogeneic trans-
plantation represents a major advance in the treatment of
older adults with AML, its curative potential remains limited
by both disease relapse and graft-versus-host disease
(GVHD), which now represent the 2 major causes of treat-
ment failure [5]. Thirty percent to 80% of patients allografted
for AMLwill relapse; the great majority in the ﬁrst 12months
after transplantation, and the outcome for this patient
population remains extremely poor [6].
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apies with the ability to either augment a GVL effect or
deliver direct antitumor activity after transplantation rep-
resents a promising strategy to reduce the risk of disease
relapse. However, because the preponderance of patients
allografted for AML relapse within the ﬁrst year after
transplantation, any intervention aimed at reducing the risk
of relapse must be delivered early. Although donor
lymphocyte infusions (DLI) have the potential to augment a
GVL effect, they are associated with a signiﬁcant risk of
severe GVHD, particularly when administered early after
transplantation, which complicates their routine utilization
[7,8]. In contrast, pharmacological agents can, in principle,
be administered early after transplantation, and conse-
quently are the subject of increasing scrutiny as a strategy
to reduce the risk of disease relapse after transplantation
[9-11].
Azacitidine (AZA) is a DNA methyltransferase inhibitor
that demonstrates signiﬁcant clinical activity in AML and
myelodysplasia [12,13] and can also be an effective salvage
therapy in patients who relapse after allogeneic trans-
plantation [14,15]. It has been postulated that the anti-
leukemic activity of AZA after transplantation may, in part
at least, be a consequence of the upregulation of epige-
netically silenced minor histocompatibility and tumor
antigens on leukemic blasts, resulting in an augmented
GVL response [16-18]. This is supported by the observation
that AZA has the capacity to induce a CD8þ T cell response
to a range of tumor antigens in patients with AML both
before and after transplantation [16,17]. Separately, AZA
has been shown to augment the reconstitution of T regu-
latory cells (Tregs) in the immediate post-transplantation
period and, in mouse models, its administration reduces
the risk of severe GVHD [17,19-21]. Taken together, these
data raise the possibility that post-transplantation AZA
may either deliver a direct antitumor effect or epigeneti-
cally manipulate the allo-immune response, augmenting a
GVL effect without increasing the risk of GVHD [22]. To
date, however, there has been no systematic study of the
clinical activity of adjunctive post-transplantation AZA
when administered as a maintenance strategy. Two small
studies have identiﬁed the maximum tolerated dose of
AZA after transplantation. None to date have studied the
impact of sustained administration of hypomethylating
agents on clinical outcome [10,11]. We, therefore, now
report clinical outcomes in a cohort of patients with AML
who underwent transplantation using a standardized RIC
regimen incorporating post-transplantation AZA in the
RICAZA study.
PATIENTS AND METHODS
Patient Inclusion
Adult patients with AML whose outcome with conventional chemo-
therapy was predicted to be poor, in whom a matched related donor
or matched unrelated donor had been identiﬁed, were eligible for this
trial. The clinical trial protocol was approved by the research ethics
committee and all patients gave informed consent in accordance with the
Declaration of Helsinki. The trial was registered at http://isrctn.org as
#ISRCTN36825171. The primary endpoint of the study was to assess the
safety and tolerability of AZA in patients after RIC allogeneic trans-
plantation for AML. The impact of AZA administration on biological
parameters in the ﬁrst 27 patients treated on the RICAZA study have been
reported in a previous publication, but with a median follow-up of
7 months, it was not possible to comment on the impact of AZA admin-
istration on clinical outcomes [17]. In this paper, we report an updated
analysis of the 37 patients treated on the RICAZA study with a median
follow-up of 24 months (range, 6 to 28 months).Transplantation Regimen
Patients who underwent allogeneic SCT using either a conditioning
regimen consisting of ﬂudarabine (30 mg/m2 intravenously for 5 days),
melphalan (140 mg/m2 intravenously), and alemtuzumab (10 mg intrave-
nously for 5 days) (n¼ 34) or a FLAMSA regimen (n¼ 3) were eligible for this
trial [23]. GVHD prophylaxis consisted of cyclosporine commencing day 1
at an adjusted dose to achieve therapeutic levels between 100 mg/L and
200 mg/L after transplantation, with the aim of tapering immunosuppression
in patients with no evidence of active GVHD between day 60 and day 90
after transplantation. Patients were not eligible to receive DLI in the ﬁrst
year after transplantation.
AZA Schedule
Patients with stable engraftment (neutrophil count:>1 109/L; platelet
count: >50  109/L) commenced treatment with AZA on day þ42 after
transplantation at a dose of 36 mg/m2 subcutaneously for 5 days. This was
administered every 28 days up to 12 months after transplantation. Toxicity
was graded against the National Cancer Institute’s Common Terminology
Criteria for Adverse Events. The dose of AZA was reduced to 24 mg/m2
in patients experiencing grade 3 or 4 hematologic toxicity that persisted
for >2 weeks. Initial data concerning the tolerability of post-transplantation
AZA in a cohort of 27 patients, of whom only 17 had received more than
6 courses of post-transplantation AZA, were presented in a previous publi-
cation [17] and we now report the ﬁnal toxicity and clinical outcome data in
the complete trial cohort of 37 patients. The presence of active acuteGVHDor
a history of GVHDwere not exclusion criteria to trial entry. Clinical responses
and transplantation outcome were assessed every 3 months by sequential
bone marrow aspirates and peripheral blood lineage speciﬁc chimerism an-
alyses, as previously described, until 12 months after transplantation.
Quantiﬁcation of Circulating Tumor-speciﬁc CD8þ T Cells
The number of circulating tumor-speciﬁc cytotoxic T lymphocytes was
measured in peripheral blood mononuclear cells prepared from 50 mL of
fresh peripheral blood using a CD137 expression and enrichment assay
(Miltenyi Biotec, Bergisch Gladbach, Germany). The procedure was con-
ducted as previously described with some minor adjustments [17,24,25].
The HLA type of each patient was known and peptides that matched the HLA
type were chosen from the list of previously described tumor-associated
antigens [17]. The frequency of CD137þ antigen-speciﬁc T cells was calcu-
lated as a percentage of the total CD8þ T cell pool from the pre-enrichment
estimates. The postenrichment analysis was used to validate the results
obtained in pre-enrichment samples.
Statistical Analysis
Safety and tolerability outcomes were deﬁned in terms of hematological
and nonhematological toxicities. Studied outcomes included rates of com-
plete remission (CR), relapse-free survival (RFS), and overall survival (OS).
RFS was deﬁned as the time from transplantation to relapse or death,
censoring alive patients at date last seen. OS was deﬁned as time from
transplantation to death, censoring alive patients at date last seen. The
sample size was calculated using A’Herns single stage design and was based
on the primary outcome measure of tolerability. A tolerability rate of 50% or
less was deemed to be unacceptable and the probability of obtaining a false
positive result was set at 5%. A tolerability rate of 70% was deemed to be an
acceptable ﬁgure and the probability of a false negative result (ie, incorrectly
rejecting for further study a treatment with a true tolerability rate of >70%)
was set at 10%. The analysis reported is based on the per-protocol popula-
tion, including all patients who received the protocol-deﬁned RIC regimen
and commenced AZA after transplantation. Statistical analyses were per-
formed using STATA 12 and R version 3.1.
RESULTS
Patient Demographics
Fifty-one patients were registered for treatment on the
RICAZA trial and underwent allogeneic transplantation.
Fourteen patients did not commence AZA therapy because
of post-transplantation complications, including infection
(n¼ 8), patient withdrawal of consent or ineligibility (n ¼ 5),
or acute GVHD (n ¼ 1). Thirty-seven patients commenced
monthly courses of AZA at a median time of 54 days after
transplantation (range, 40 to 194 days) and are the subject
of this report. The median follow-up for alive patients was
24 months (range, 6 to 28 months). The median age of the
37 patients who commenced AZA was 60 years (range, 40
Table 1
Demographics of Study Population
Characteristic Value
Diagnosis
AML, de novo 24
AML, secondary 13
Karyotype
Intermediate 30
Poor 7
Age, median (range), yr 60 (40-71)
Sex
Male 21
Female 16
Disease status at time of transplantation
CR1 24
CR2 8
First relapse 3
Primary refractory disease 2
Conditioning treatment
Fludarabine, melphalan, alemtuzumab 34
Fludarabine, cytarabine, amsacrine 3
Donor type
Sibling 13
Matched unrelated donor 24
CMV status (patient/donor)
Positive/positive 14
Positive/negative 6
Negative/positive 3
Negative/negative 14
Stem cell source
Peripheral blood 34
Bone marrow 3
CMV indicates cytomegalovirus.
Table 2
Summary of Hematological and Nonhematological Adverse Events Occur-
ring in >10% of the Patient Population
Grades
1-2
Grades
3-4
Total
Hematological Adverse Event
Anemia 16 10 26
Thrombocytopenia 10 13 23
Neutropenia 3 10 13
Nonhematological Adverse Event
Laboratory investigations e
biochemistry
75 10 85
Gastrointestinal (inc. nausea, vomiting,
diarrhea, constipation, anorexia)
71 2 73
Infection 35 19 54
Injection site reaction 28 0 28
Pain 21 2 23
Dermatology/skin (rash, mucositis,
pruritus, shingles, dry skin, bruising,
itching, peeling epidermis, skin
breakdown)
21 0 21
Fatigue/lethargy 20 0 20
Pulmonary/upper respiratory (cough,
dyspnea, hypoxia)
12 1 13
Neurology (headache, depression,
apnea, syncope)
7 2 9
Fever 6 1 8
Cold/ﬂu-like symptoms 8 0 8
Edema 4 0 4
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CR1, 8 patients (22%) were in CR2, 3 patients (8%) were in
ﬁrst relapse, and 2 patients (5%) had primary refractory
disease (Table 1). Thirteen (35%) patients underwent trans-
plantation using a matched related donor and 24 (65%) had
an adult volunteer unrelated donor. Thirty-four patients
received granulocyte colonyestimulating factoremobilized
peripheral blood stem cells and 3 had bone marrow as the
stem cell source. All patients engrafted with a median time
to neutrophil engraftment of 13 days (range, 1 to 22 days)
and a median time to platelet engraftment of 13 days (range,
10 to 33 days).Tolerability of Post-transplantation AZA
AZA was well tolerated in the majority of patients.
Hematological and nonhematological toxicities experienced
by 10% or more of patients are described in Table 2. Four
patients experienced treatment delays due to neutropenia or
thrombocytopenia. The most common nonhematological
toxicities observed were abnormalities of liver function,
injection site reaction, nausea, and infection. Thirty-one
patients completed at least 3 cycles of AZA and 16 patients
completed 10 cycles. Twenty patients discontinued AZA
before 12 months after transplantation because of disease
relapse (n ¼ 10), infection or hematological toxicity (n ¼ 6),
or miscellaneous reasons (eg, physician decision to admin-
ister DLI, withdrawal of consent, and protocol deviation)
(n ¼ 4).Chimerism, GVHD, Relapse, and Outcome
At day þ90 after transplantation, 22 (59%) patients
demonstrated full donor chimerism inwhole blood, of whom
7 (19%) demonstrated full donor chimerism in the T cell
fraction. Serial chimerism studies are available on 14 patientswho received AZA after transplantation, which demonstrate
broad stability of T cell chimerism with no signiﬁcant
changes observed over time. Grade 1 or 2 acute GVHD was
documented in 17 patients. No patient developed severe
(grades 3 or 4) acute GVHD during the period of treatment on
the RICAZA trial, although 1 patient developed severe GVHD
after being withdrawn and receiving DLI for the treatment of
disease relapse. Ten patients developed limited chronic
GVHD but no patient developed extensive chronic GVHD.
The day 100 nonrelapse mortality was 0% and the 1-year
nonrelapse mortality was 8% (all infectious deaths). A total
of 19 (51%) patients died (disease relapse, n ¼ 16; infection,
n ¼ 2; DLI-induced GVHD, n ¼ 1). The median time to
disease relapse was 8 months after transplantation (range,
5 to 11 months). The 1-year and 2-year OS were 81% (95%
conﬁdence interval [CI], 69% to 95%) and 49% (95% CI, 35%
to 68%), respectively. The 1-year and 2-year RFS were 57%
(95% CI, 43% to 75%) and 49% (95% CI, 35% to 68%),
respectively.
Correlation of Peripheral Blood Antitumor CD8-speciﬁc T
Cell Response with Clinical Outcome
Twenty-eight patients treated with AZA were screened
for antitumor CD8þ T cell responses to a range of tumor
antigens. AZA induced a CD8þ T cell response to 1 or more
tumor-speciﬁc peptides in 16 patients. A summary of their
characteristics by CD8 T cell response is displayed in Table 3.
As previously reported, no CD8þ Tcell responsewas detected
in 7 patients allografted using a similar conditioning regimen
who did not receive AZA after transplantation [17]. The
frequency of CD8þ T cells directed against the studied tumor
antigens ranged from .01% to 1.6% (mean, .45%) of circulating
CD8þ T cells, which is comparable to the frequency of
cytomegalovirus-speciﬁc T cell responses detectable in
cytomegalovirus-seropositive patients. Induction of a CD8þ
anti-tumor response was associated with a reduction in
relapse risk taking into account death as a competing risk
(hazard ratio [HR], .30; 95% CI, .10 to .85; P ¼ .02) and
Table 3
Demographics of Patients with CD8 T Cell Response
Characteristic CD8 Negative
(n ¼ 12)
CD8 Positive
(n ¼ 16)
Age, years (mean, range) 61 (41-70) 59 (49-71)
Sex
Male 7 10
Female 5 6
Disease status at time of transplantation
CR1 8 11
CR2 3 4
First relapse 1 1
Donor type
Sibling 4 8
Matched unrelated donor 8 8
CMV status (patient/donor)
Positive/positive 4 7
Positive/negative 3 2
Negative/positive 0 3
Negative/negative 5 4
Stem cell source
Peripheral blood 11 15
Bone marrow 1 1
Time from transplantation to start
of AZA, median (range), d
47 (40-81) 57 (40-194)
C. Craddock et al. / Biol Blood Marrow Transplant 22 (2016) 378e393388improved RFS (HR, .29; 95% CI, .10 to .83; P ¼ .02) (Figure 1).
The beneﬁcial impact of detection of a CD8þ T cell response
to candidate tumor antigens on relapse risk and RFS is still
observed, with adjustment for time to start of AZA therapy
(HR, .30; 95% CI, .1 to .94; P ¼ .039) or if restricted to only
24 patients who commenced AZA before day þ90 after
transplantation (HR, .32; 95% CI, .10 to .95; P ¼ .041) in the
competing risk analysis.
The impact of detection of a CD8þ T cell response on
relapse risk remains strong with adjustment of donor type
(HR, .26; 95% CI, .09 to .70; P ¼ .008) and with additional
adjustment of start time to AZA therapy after transplantation
(HR, .27; 95% CI, .09 to .82; P¼ .022). Therewas no correlation
between the timing or magnitude of the CD8þ tumor
response and relapse risk.Figure 1. RFS of patients according to post-transplanDISCUSSION
The ability of epigenetic therapies to upregulate tumor
antigens represents a novel strategy by which a GVL
response may be augmented. In this small prospective trial,
we observed a reduced risk of disease relapse in patients
treated with post-transplantation AZA who developed a
CD8þ T cell response to a range of candidate tumor antigens.
It is important to emphasize the importance of repeating this
observation in a larger randomized study, but these data are
supportive of further investigation of the impact of other
post-transplantation epigenetic therapies, such as DNA
methyltransferase inhibitor and histone deacetylase in-
hibitors, on transplantation outcome. Of interest, the dose of
AZA observed to induce a CD8þ Tcell response in this study is
approximately one-half that utilized in the treatment of
patients with de novo AML or myelodysplasia, consistent
with the hypothesis that the observed reduction in relapse is
consequent upon manipulation of the alloreactive response.
Our study appears to refute the possibility that AZA might
improve/outcome by simply postponing relapse, although a
larger study will clearly be required to conclusively address
this possibility. Because the great majority of patients
destined to relapse after an allogeneic transplantation for
AML will do so within the ﬁrst year, a potential advantage of
AZA administration, as opposed to DLI, is the ability to
commence treatment early [6]. The majority of patients in
this study were not only able to commence AZA within 3
months after transplantation but also complete the sched-
uled course of 1-year treatment. Nonetheless, approximately
one third of the patients registered to this study did not
receive AZA, emphasizing the potential limitations of post-
transplantation interventions as a strategy to reduce the
risk of disease relapse. Alternative approaches to selectively
augment a GVL effect include vaccination to tumor antigens,
such as WT1, and it would be of interest to combine such
a strategy with AZA, as has been done for DLI [26,27].
Furthermore, although in this study we measured T cell re-
sponses to a broad range of candidate tumor antigens, futuretation CD8þ T cell response to tumor antigens.
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with the induction of immune responses to speciﬁc tumor
antigens.
A number of studies have demonstrated the ability of AZA
to accelerate the reconstitution of Tregs after allogeneic
SCT [17,21], and in murine models this has been correlated
with a reduction in the incidence of GVHD [19]. Although
the observation that no patient who received post-
transplantation AZA had extensive chronic GVHD is strik-
ing, particularly given the fact that most patients underwent
transplantation using an unrelated donor, it is important to
note that the RIC regimen utilized included alemtuzumab,
which is known to reduce the incidence of both acute and
chronic GVHD [28,29]. Nonetheless, these data support
further examination of the impact of post-transplantation
AZA on the incidence of acute or chronic GVHD. Reassur-
ingly, our data suggest that the observed induction of Tregs
and attendant absence of extensive chronic GVHD do not
appear to be associated with an increased risk of disease
relapse [22].
This is the ﬁrst study to examine the impact of the post-
transplantation administration of AZA on transplantation
outcome. The reduced relapse rate in patients who demon-
strate a CD8þ Tcell response directed against tumor antigens,
coupled with the absence of chronic extensive GVHD, is
consistent with the hypothesis that AZA has the capacity to
epigenetically manipulate the alloreactive effect after trans-
plantation. These observations require conﬁrmation in a
prospective randomized trial.ACKNOWLEDGMENTS
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Old agea b s t r a c t
The maximum age of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has
been moving up over time. However, the availability of a suitable HLA-matched sibling donor may limit access
of this patient population to alloHCT. We retrospectively investigated the outcomes of umbilical cord blood
transplantation (UCBT) after reduced-intensity conditioning regimens in patients aged 70 years with
myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) between 2010 and 2014. During
this period 70 patients with AML/MDS were referred to our center for alloHCT consideration. Twenty-two
patients (33%) received alloHCT: 10 UCBT, 9 HLA full-matched sibling donor transplantation, 2 hap-
loidentical alloHCT, and 1 unrelated donor alloHCT. In UCBT, cumulative incidences of nonrelapse mortality
and relapse were 20% and 30% at 2 years, respectively. The cumulative incidence of acute graft-versus-host
disease (GVHD) at day þ100 and chronic GVHD at 2 years was 10%. Seven patients had viral reactivation/
infections. Rates of overall survival and disease-free survival were 60% and 50% at 2 years, respectively.
Moreover, these outcomes seemed to be similar to that of patients aged 60 to 69 years receiving UCBT
(n ¼ 60) and patients aged 70 years receiving HLA full-matched sibling donor transplantation (n ¼ 9). These
results suggest that UCBT is feasible in selected AML/MDS patients aged 70 years. In fact, UCBT shortens the
required time for an unrelated donor search and thus increases the chance of proceeding with alloHCT, which
might contribute to higher rates of alloHCT in the referral group. Outcomes of UCBT are promising; however,
larger studies with a longer follow-up are needed.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION with myeloablative conditioning regimens, less frequent
Acute myelogenous leukemia (AML) and myelodysplastic
syndrome (MDS) are more frequent in older patients, and
elderly patients have poor survival compared with younger
patients [1]. Elderly AML patients who are treated may have
better outcomes [1]; however, even in patients who achieve
complete remission, their overall survival (OS) can still
be poor [2]. Allogeneic hematopoietic cell transplantation
(alloHCT) may improve outcomes in older patients with AML
and MDS in complete remission [3-5]. However, traditionally
set age limits, increased risk of nonrelapse mortality (NRM)availability of a suitable HLA-matched sibling donor (MSD) or
unrelated donor (URD), and difﬁculties in timing and deci-
sion making process [6] may preclude this treatment option
from the elderly population.
A study from the Center for International Blood and
Marrow Transplant Research suggested that older patients
(60 years) with AML/MDS had similar NRM and OS than
younger age groups [7]. Moreover, a study showed that
alloHCT fromMSDs or URDs is feasible and reasonably safe in
a selected elderly (70 years) population [8]. We previously
reported the feasibility of umbilical cord blood (UCB) as an
alternative donor source using reduced-intensity condition-
ing (RIC) in patients aged 55 to 70 [9]. In this current study
we evaluated our experience with the outcomes of UCB
transplantation (UCBT) in AML/MDS patients aged70 years,
focusing on early NRM. We looked at graft-versus-host
disease (GVHD)/relapse-free survival and the survival out
of hospital (ie, days alive and out of hospital) as surrogate
markers for quality of life.
